A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Inclusion Criteria: * Adults participants aged 18 years or older * Confirmed diagnosis of primary sclerosing cholangitis based on standard clinical, biochemical, and imaging criteria * Compensated liver disease at screening * Stable background therapy, where applicable prior to study entry * Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control * Ability to provide written informed consent and comply with study procedures. Exclusion Criteria: \- History or presence of other concomitant chronic liver disease \- History of hepatic decompensation, including: i) History of liver transplantation, current MELD 3.0 score ≥12 due to hepatic impairment. ii) Evidence of complications of cirrhosis * Participants with cirrhosis who are also classified as Child-Pugh B or C based on the Child Pugh score. * History of biliary intervention within 60 days prior to the screening period, and/or presence of percutaneous drain or bile duct stent at SV. * History of bacterial cholangitis, and/or participant on antibiotics for prophylaxis of recurrent cholangitis within 60 days prior to the SV. * History or any current suspicion of cholangiocarcinoma or hepatocellular carcinoma * Known malignancy or history of malignancy within the last 5 years, with the exception of local, successfully treated basal cell carcinoma or in-situ carcinoma of the uterine cervix. * Medical conditions that may cause non-hepatic increases in …